Straits Times Index
3,272.72 +47.55 (+1.47%) S&P 500
5,070.55 +59.95 (+1.20%) Dow
38,503.69 +263.71 (+0.69%) Nasdaq
15,696.64 +245.33 (+1.59%) Bitcoin USD
66,421.24 -94.36 (-0.14%) CMC Crypto 200
1,426.91 +12.15 (+0.86%)
Sol-Gel Technologies Ltd. (SLGL)
After hours:
| Previous close | 0.9214 |
| Open | 0.9750 |
| Bid | 0.0000 x 0 |
| Ask | 0.0000 x 0 |
| Day's range | 0.9252 - 0.9750 |
| 52-week range | 0.7900 - 4.0500 |
| Volume | |
| Avg. volume | 32,450 |
| Market cap | 25.774M |
| Beta (5Y monthly) | 1.32 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -1.0100 |
| Earnings date | 10 May 2024 - 14 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 8.00 |
GlobeNewswireSol-Gel’s Collaboration Partner First-to-File ANDA Drug Product Generic to Zoryve® Cream
Patent challenge initiated by Arcutis BiotherapeuticsNESS ZIONA, Israel, April 01, 2024 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a dermatology company pioneering treatments for patients with severe skin conditions, conducting a Phase 3 clinical trial of SGT-610 (patidegib gel, 2%) for Gorlin syndrome, and with two approved large-category dermatology products, TWYNEO® and EPSOLAY®, today announced that Padagis Israel Pharmaceuticals Ltd (“Padagis”), Sol-Gel’s collaboration p
Simply Wall St.Sol-Gel Technologies Full Year 2023 Earnings: Revenues Beat Expectations, EPS In Line
Sol-Gel Technologies ( NASDAQ:SLGL ) Full Year 2023 Results Key Financial Results Net loss: US$27.2m (loss widened by...
- GlobeNewswire
Sol-Gel Reports Full-Year 2023 Financial Results and Corporate Developments
An ongoing phase 3 clinical trial of SGT-610 for Gorlin Syndrome with the first patient screened; Results are expected by the end of 2025 Sol-Gel maintains a cash runway into the second half of 2025 NESS ZIONA, Israel, March 13, 2024 (GLOBE NEWSWIRE) -- Sol-Gel Technologies, Ltd. (NASDAQ: SLGL), a dermatology company with an innovative pipeline and approaches to develop a pioneering treatment for patients with severe skin conditions, is conducting a phase 3 clinical trial of SGT-610 (Patidegib g
